AR132255A1 - Compuestos de fusión y usos de estos - Google Patents
Compuestos de fusión y usos de estosInfo
- Publication number
- AR132255A1 AR132255A1 ARP240100762A ARP240100762A AR132255A1 AR 132255 A1 AR132255 A1 AR 132255A1 AR P240100762 A ARP240100762 A AR P240100762A AR P240100762 A ARP240100762 A AR P240100762A AR 132255 A1 AR132255 A1 AR 132255A1
- Authority
- AR
- Argentina
- Prior art keywords
- fusion
- polypeptide
- glp
- fgf21
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención se refiere a proteínas de fusión que comprenden un polipéptido GLP-1 y un polipéptido FGF21 separados por espaciadores. La invención se refiere, además, a compuestos de fusión que comprenden las proteínas de fusión y al menos un sustituyente. La invención también se refiere al uso farmacéutico de los compuestos de fusión. Reivindicación 1: Una proteína de fusión que comprende un polipéptido de la Sustancia Quím. 1: A-B-C, en donde: (i) A es un polipéptido GLP-1, que es un análogo de GLP-1 (7-37) (SEQ ID Nº 1), (i) B es un espaciador que consiste en 1 - 257 aminoácidos, y (i) C es un polipéptido FGF21, que es un análogo de FGF21 (1-181) (SEQ ID Nº 2); o una sal, amida o éster farmacéuticamente aceptable de este. Reivindicación 9: Un compuesto de fusión que comprende una proteína de fusión de acuerdo con una cualquiera de las reivindicaciones 1 - 8 y uno o más sustituyentes.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP23165485 | 2023-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR132255A1 true AR132255A1 (es) | 2025-06-11 |
Family
ID=85792541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240100762A AR132255A1 (es) | 2023-03-30 | 2024-03-27 | Compuestos de fusión y usos de estos |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240400635A1 (es) |
| KR (1) | KR20250167609A (es) |
| CN (1) | CN120936621A (es) |
| AR (1) | AR132255A1 (es) |
| AU (1) | AU2024241939A1 (es) |
| CO (1) | CO2025013304A2 (es) |
| IL (1) | IL323581A (es) |
| MX (1) | MX2025011287A (es) |
| TW (1) | TW202438102A (es) |
| WO (1) | WO2024199734A2 (es) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| EP2440235A1 (en) | 2009-06-11 | 2012-04-18 | Novo Nordisk A/S | Glp-1 and fgf21 combinations for treatment of diabetes type 2 |
| AU2016202945A1 (en) * | 2011-09-26 | 2016-05-26 | Irm Llc | Dual function proteins for treating metabolic disorders |
| EP2892919A1 (en) * | 2012-09-07 | 2015-07-15 | Sanofi | Fusion proteins for treating a metabolic syndrome |
| MX377044B (es) | 2014-12-23 | 2025-03-07 | Novo Nordisk As | Derivados del factor 21 de crecimiento de fibroblastos (fgf21) y sus usos. |
| CN110028587B (zh) * | 2018-01-11 | 2021-10-08 | 安源医药科技（上海）有限公司 | 用于调节血糖和脂质的增效型双功能蛋白 |
| CN108610398B (zh) * | 2018-01-15 | 2020-08-11 | 武汉海特生物制药股份有限公司 | 一段功能序列及在分泌蛋白表达中的应用 |
| CN115322794B (zh) * | 2020-01-11 | 2025-09-19 | 北京质肽生物医药科技有限公司 | Glp-1和fgf21的融合蛋白的缀合物 |
-
2024
- 2024-03-27 AR ARP240100762A patent/AR132255A1/es unknown
- 2024-03-27 WO PCT/EP2024/025136 patent/WO2024199734A2/en not_active Ceased
- 2024-03-27 CN CN202480023448.7A patent/CN120936621A/zh active Pending
- 2024-03-27 AU AU2024241939A patent/AU2024241939A1/en active Pending
- 2024-03-27 KR KR1020257032222A patent/KR20250167609A/ko active Pending
- 2024-03-28 TW TW113111725A patent/TW202438102A/zh unknown
- 2024-07-19 US US18/778,518 patent/US20240400635A1/en active Pending
-
2025
- 2025-09-24 MX MX2025011287A patent/MX2025011287A/es unknown
- 2025-09-25 IL IL323581A patent/IL323581A/en unknown
- 2025-09-29 CO CONC2025/0013304A patent/CO2025013304A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202438102A (zh) | 2024-10-01 |
| CN120936621A (zh) | 2025-11-11 |
| MX2025011287A (es) | 2025-11-03 |
| IL323581A (en) | 2025-11-01 |
| US20240400635A1 (en) | 2024-12-05 |
| WO2024199734A3 (en) | 2024-11-07 |
| CO2025013304A2 (es) | 2025-12-19 |
| KR20250167609A (ko) | 2025-12-01 |
| AU2024241939A1 (en) | 2025-10-02 |
| WO2024199734A2 (en) | 2024-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Goraya et al. | Ranatuerins: antimicrobial peptides isolated from the skin of the American bullfrog, Rana catesbeiana | |
| CA2179286C (en) | Broad spectrum antimicrobial compounds and methods of use | |
| Rifflet et al. | Identification and characterization of a novel antimicrobial peptide from the venom of the ant Tetramorium bicarinatum | |
| ES2657344T3 (es) | Nuevos mutantes de proNGF y usos de los mismos en la producción de beta-NGF | |
| US5830993A (en) | Synthetic antimicrobial peptide | |
| US20020025918A1 (en) | Methods of using helical peptides in plants | |
| AR005651A1 (es) | Proteina de fusion, vector de expresion para dicha proteina, cepa de escherichia coli que expresa dicha proteina, uso de dicha proteina, composicion de vacuna que comprende la proteina, metodo para la purificacion de la proteina y anticuerpo monoclonal empleado en el metodo | |
| JPH04506803A (ja) | 小環状血小板凝集阻害剤 | |
| RS63298B1 (sr) | Egf(a) analozi sa supstituentima masnih kiselina | |
| RU94046251A (ru) | Глюкагоноподобный пептид и производные инсулино-тропина, способ получений, фармацевтические композиции, способы лечения диабета | |
| US5965536A (en) | Methods of inhibiting CXC intercrine molecules | |
| US6566334B1 (en) | Short amphipathic peptides with activity against bacteria and intracellular pathogens | |
| PT1439231E (pt) | ''rantes truncada na extremidade amino como antagonistaas de quimiocinas'' | |
| KR20010052340A (ko) | 인돌리시딘 유사체 및 그 사용 방법 | |
| Carr et al. | Disulfide assignments in recombinant mouse and human interleukin 4 | |
| WO2025208807A1 (zh) | 一种抗菌肽Thanatin衍生肽及其医药用途 | |
| US6090795A (en) | Human derived monocyte attracting purified peptide products useful in a method of treating infection and neoplasms in a human body | |
| Dohtsu et al. | Isolation and sequence analysis of peptides from the venom of Protonectarina sylveirae (hymenoptera‐vespidae) | |
| ES2602436T3 (es) | Inhibidor basado en péptido de la activación de interleucina 10 o STAT-3 | |
| AR132255A1 (es) | Compuestos de fusión y usos de estos | |
| US20060165650A1 (en) | Rantes-derived peptides with anti-hiv activity | |
| AR123189A1 (es) | VACUNA DE SINUCLEÍNA a PARA EL TRATAMIENTO DE SINUCLEINOPATÍAS | |
| Čemažar et al. | Oxidative folding of cyclic cystine knot proteins | |
| Xiao et al. | Antimicrobial peptides from amphibians | |
| Kirichenko et al. | Complete synthesis of the bicyclic ring of a mutacin analog with orthogonally protected lanthionine via solid‐phase intracyclization |